

PTO-1449 REPRODUCED

**INFORMATION DISCLOSURE CITATION
IN AN APPLICATION**

MAY 24 2004

May 11, 2004

(Use several sheets if necessary)

ATTORNEY DOCKET NO.
1932.2135-002

APPLICATION NO.
10/686,808

FIRST NAMED INVENTOR
Steven K. Burke

FILING DATE
October 16, 2003

EXAMINER
Not Yet Assigned

CONFIRMATION NO.
8791

GROUP
1646

U.S. PATENT DOCUMENTS

EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
AS	AA	US 2002/0051822 A1	05-02-2002	Atherton <i>et al.</i>
	AB	5,487,888	01-30-1996	Mandeville, III <i>et al.</i>
	AC	5,496,545	03-05-1996	Holmes-Farley <i>et al.</i>
	AD	5,607,669	03-04-1997	Mandeville, III <i>et al.</i>
	AE	5,618,530	04-08-1997	Mandeville, III <i>et al.</i>
	AF	5,624,963	04-29-1997	Mandeville, III <i>et al.</i>
	AG	5,667,775	09-16-1997	Mandeville, III <i>et al.</i>
	AH	5,679,717	09-16-1997	Holmes-Farley <i>et al.</i>
	AI	5,703,188	12-30-1997	Mandeville, III <i>et al.</i>
	AJ	5,702,696	12-30-1997	Mandeville, III <i>et al.</i>
	AK	5,693,675	12-02-1997	Mandeville, III <i>et al.</i>
	AA2	5,900,475	05-04-1999	Mandeville, III <i>et al.</i>
	AB2	5,925,379	07-20-1999	Mandeville, III <i>et al.</i>
	AC2	6,083,497	07-04-2000	Huval <i>et al.</i>
	AD2	6,177,478	01-23-2001	Holmes-Farley <i>et al.</i>
	AE2	6,083,495	07-04-2000	Holmes-Farley <i>et al.</i>
	AF2	6,203,785	03-20-2001	Holmes-Farley <i>et al.</i>
	AG2	6,423,754	07-23-2002	Holmes-Farley <i>et al.</i>
	AH2	6,509,013	01-21-2003	Holmes-Farley <i>et al.</i>
	AI2	6,556,407	04-29-2003	Brando <i>et al.</i>
	AJ2	US 2002/0159968 A1	10-31-2002	Petersen <i>et al.</i>
	AK2	US 2003/0086898 A1	05-08-2003	Holmes-Farley <i>et al.</i>
	AA3	US 2003/0133902 A1	07-17-2003	Holmes-Farley <i>et al.</i>
	AB3	6,726,905	04-27-2004	Mandeville, III <i>et al.</i>
	AC3	6,733,780	05-11-2004	Tyler <i>et al.</i>
AS	AD3	US 2002/0182168 A1	12-05-2002	Holmes-Farley <i>et al.</i>

EXAMINER

DATE CONSIDERED

8-2-06

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 11, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1932.2135-002	APPLICATION NO. 10/686,808	
	FIRST NAMED INVENTOR Steven K. Burke		FILING DATE October 16, 2003
	EXAMINER Not Yet Assigned	CONFIRMATION NO. 8791	GROUP 1646

U.S. PATENT DOCUMENTS				
EXAM- INER INI- TIAL	REF. NO.	DOCUMENT NUMBER Number-Kind Code (if known)	ISSUE DATE / PUBLICATION DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT
<i>JS</i>	AE3	6,566,407	05-20-2003	Holmes-Farley <i>et al.</i>
<i>JS</i>	AF3	US 2002/0187120 A1	12-12-2002	Holmes-Farley <i>et al.</i>
<i>JS</i>	AG3	US 2002/0168333 A1	11-14-2002	Burke
<i>JS</i>	AH3	US 2002/0187121 A1	12-12-2002	Burke
<i>JS</i>	AI3	US 2003/0049226 A1	03-13-2003	Burke <i>et al.</i>
<i>JS</i>	AJ3	US 2003/0039627 A1	02-27-2003	Holmes-Farley <i>et al.</i>


FOREIGN PATENT DOCUMENTS					
		DOCUMENT NUMBER Country Code-Number-Kind Code (if known)	DATE MM-DD-YYYY	NAME OF PATENTEE OR APPLICANT OF CITED DOCUMENT	TRANSLATION YES NO
<i>JS</i>	AL	WO 03/057225 A2	07-17-2003	Genzyme Corporation	
<i>JS</i>	AM	WO 93/04373	03-04-1993	NPS Pharmaceuticals, Inc.	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
<i>JS</i> AR	Moe, S., <i>et al.</i> , "Sevelamer HCL Improves Parathyroid Hormone (PTH) and Bone Function in Peritoneal Dialysis (PD) Patients With Probable Low Turnover Bone Disease," <i>American J. of Kidney Diseases</i> , 37(4): A25 (abstract only-Tenth Annual Clinical Nephrology Meeting Abstracts), (2001).
AS	Raggi, P., <i>et al.</i> , "Sevelamer Preserves and Calcium Reduces Trabecular Bone Mineral Density," <i>J. American Society of Nephrology</i> , 14: 502A (abstract only), (2003).
AT	Katsumata, K., <i>et al.</i> , "Sevelamer Hydrochloride Prevents Ectopic Calcification and Renal Osteodystrophy in Chronic Renal Failure Rats," <i>Kidney International</i> , 64: 441-450 (2003).
<i>JS</i> AU	Slatopolsky, E.A., <i>et al.</i> , "RenaGel®, a Nonabsorbed Calcium- and Aluminum-Free Phosphate Binder, Lowers Serum Phosphorus and Parathyroid Hormone," <i>Kidney International</i> , 55: 299-307 (1999).



EXAMINER <i>Leah Schmitt</i>	DATE CONSIDERED 8-2-06
---------------------------------	---------------------------


PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 11, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1932.2135-002		APPLICATION NO. 10/686,808	
	FIRST NAMED INVENTOR Steven K. Burke		FILING DATE October 16, 2003	
	EXAMINER Not Yet Assigned	CONFIRMATION NO. 8791	GROUP 1646	

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
AV	✓	Chertow, G.M., et al., "Sevelamer With and Without Calcium and Vitamin D: Observations From a Long-Term Open-Label Clinical Trial," <i>J. Of Renal Nutrition</i> , 10(3): 125-132 (2000).
AW	✓	Chertow, G.M., et al., "Hyperparathyroidism and Dialysis Vintage," <i>Clinical Nephrology</i> , 54(4): 295-300 (2000).
AX	✓	Malluche, H.H., and Mawad, H., "Management of Hyperphosphataemia of Chronic Kidney Disease: Lessons From the Past and Future Directions," <i>Nephrol. Dial. Transplant.</i> , 17: 1170-1175 (2002).
AY	✓	Cannata-Andía, J.B., and Rodríguez-García, M., "Hyperphosphataemia as a Cardiovascular Risk Factor -How to Manage the Problem," <i>Nephrol. Dial. Transplant.</i> , 17(Suppl. 11): 16-19 (2002).
AZ	✓	Nolan, C.R., and Qunibi, W.Y., "Calcium Salts in the Treatment of Hyperphosphatemia in Hemodialysis Patients," <i>Current Opinion in Nephrology and Hypertension</i> , 12: 373-379 (2003).
AR2	✓	Čižman, B., "Hyperphosphataemia and Treatment With Sevelamer in Haemodialysis Patients," <i>Nephrol. Dial. Transplant.</i> , 18(Suppl. 5): v47-v49 (2003).
AS2	✓	Coco, M., and Rush, H., "Increased Incidence of Hip Fractures in Dialysis Patients With Low Serum Parathyroid Hormone," <i>Am. J. Kidney Diseases</i> , 36(6): 1115-1121 (2000).
AT2	✓	Taal, M.W., et al., "Risk Factors for Reduced Bone Density in Haemodialysis Patients," <i>Nephrol. Dial. Transplant.</i> , 14: 1922-1928 (1999).
AU2	✓	Taal, M.W., et al., "Total Hip Bone Mass Predicts Survival in Chronic Hemodialysis Patients," <i>Kidney International</i> , 63: 1116-1120 (2003).
AV2	✓	Braun, J., et al., "Electron Beam Computed Tomography in the Evaluation of Cardiac Calcifications in Chronic Dialysis Patients," <i>American J. Kidney Diseases</i> , 27(3): 394-401 (1996).
AW2	✓	Cozzolino, M., et al., "Role of Calcium-Phosphate and Bone-Associated Proteins on Vascular Calcification in Renal Failure," <i>J. Am. Soc. Nephrol.</i> , 12: 2511-2516 (2001).
AX2	✓	Loghman-Adham, M., "Phosphate Binders for Control of Phosphate Retention in Chronic Renal Failure," <i>Pediatr. Nephrol.</i> , 13: 701-708 (1999).
AY2	✓	Elder, G., "Pathophysiology and Recent Advances in the Management of Renal Osteodystrophy," <i>J. Bone and Mineral Research</i> , 17(12): 2094-2105 (2002).

EXAMINER 	DATE CONSIDERED 8-2-06
---	---------------------------

PTO-1449 REPRODUCED INFORMATION DISCLOSURE CITATION IN AN APPLICATION May 11, 2004 (Use several sheets if necessary)	ATTORNEY DOCKET NO. 1932.2135-002		APPLICATION NO. 10/686,808	
	FIRST NAMED INVENTOR Steven K. Burke		FILING DATE October 16, 2003	
	EXAMINER Not Yet Assigned		CONFIRMATION NO. 8791	GROUP 1646

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)	
	AZ2 ✓ Bardin, T., "Musculoskeletal Manifestations of Chronic Renal Failure," <i>Curr. Opin. Rheumatol.</i> , 15: 48-54 (2003).
	AR3 ✓ Albaaj, F., and Hutchison, A.J., "Hyperphosphataemia in Renal Failure (Causes, Consequences and Current Management)," <i>Drugs</i> , 63(6): 577-596 (2003).
	AS3 ✓ Martin, C.J., and Reams, S.M., "The Renal Dietitian's Role in Managing Hyperphosphatemia and Secondary Hyperparathyroidism in Dialysis Patients: A National Survey," <i>J. Renal Nutrition</i> , 13(2): 133-136 (2003).
	AT3 ✓ Fontaine, M.A., <i>et al.</i> , "Fracture and Bone Mineral Density in Hemodialysis Patients," <i>Clinical Nephrol.</i> , 54(3): 218-226 (2000).
	AU3 ✓ Kleinpeter, M.A., "Spectrum of Complications Related to Secondary Hyperparathyroidism in a Peritoneal Dialysis Patient," <i>Advances in Peritoneal Dialysis</i> , 16: 286-290 (2000).
	AV3 ✓ Chertow, G.M., <i>et al.</i> , "Poly(allylamine hydrochloride) (RenaGel®): a noncalcemic phosphate binder for the treatment of hyperphosphatemia in chronic renal failure," <i>Am. J. Kid. Dis.</i> , 29: 66-71 (1997).
	AW3 ✓ Goldberg, D.I., <i>et al.</i> , "Effect of RenaGel, a non-absorbed, calcium-and aluminum-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients," <i>Nephrol. Dial. Transplant.</i> , 13: 2303-2310 (1998).
	AX3 ✓ Chertow, G.M., <i>et al.</i> , "A randomized trial of sevelamer hydrochloride (RenaGel®) with and without supplemental calcium. Strategies for the control of hyperphosphatemia in hemodialysis patients," <i>Clin. Nephrol.</i> , 51: 18-26 (1999).
	AY3 ✓ Bleyer, A.J., <i>et al.</i> , "A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients," <i>Am. J. Kid. Dis.</i> , 33: 694-701 (1999).
	AZ3 ✓ Chertow, G.M., <i>et al.</i> , "Long-term effects of sevelamer hydrochloride on the calcium x phosphorus product and lipid profile of haemodialysis patients," <i>Nephrol. Dial. Transplant.</i> , 14: 2907-2914 (1999).
	AR4 ✓ Chertow, G.M., <i>et al.</i> , "Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients," <i>Kidney Int.</i> , 62: 245-252 (2002).
	

EXAMINER 	DATE CONSIDERED 8-2-06
--	------------------------